Zerbaxa

Zerbaxa

Manufacturer:

Merck Sharp & Dohme

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Ceftolozane 1 g, tazobactam 500 mg
Indications/Uses
Infections caused by susceptible microorganisms in complicated intra-abdominal infections in combination w/ metronidazole & complicated UTI, including pyelonephritis.
Dosage/Direction for Use
Adult ≥18 yr Complicated intra-abdominal infections 1.5 g every 8 hr for 4-14 days in conjunction w/ metronidazole 500 mg IV every 8 hr. Complicated UTI 1.5 g every 8 hr for 7 days. CrCl 30-50 mL/min 750 mg IV every 8 hr, 15-29 mL/min 375 mg IV every 8 hr. End-stage renal disease (ESRD) on hemodialysis Single loading dose: 750 mg followed by maintenance dose: 150 mg every 8 hr for the remainder of treatment period.
Contraindications
Hypersensitivity to ceftolozane, tazobactam, other cephalosporins. Severe hypersensitivity (eg, anaphylactic & severe skin reaction) to other β-lactam antibacterial agents (eg, penicillins or carbapenems).
Special Precautions
Not for direct inj. Cross-sensitivity to other cephalosporins, penicillins or other β-lactams. Clostridium difficile-associated diarrhea (CDAD). Risk of development of drug-resistant bacteria. Renal impairment. Pregnancy & lactation. Elderly ≥65 yr.
Adverse Reactions
Nausea, diarrhea, headache, pyrexia, insomnia, vomiting, hyperkalemia. Hypersensitivity, CDAD.
Drug Interactions
Prolonged tazobactam t½ by probenecid.
MIMS Class
ATC Classification
J01DI54 - ceftolozane and beta-lactamase inhibitor ; Belongs to the class of other cephalosporins and penems. Used in the systemic treatment of infections.
Presentation/Packing
Form
Zerbaxa powd for inj (vial)
Packing/Price
((1.5 g)) 10 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in